Feit Rachel, Taneri Suphi, Azar Dimitri T, Chen Chun Chen, Ang Robert T
Cornea and Refractive Surgery Service, Massachussets Eye and Ear Infirmary, Schepens Eye Research Institute, Harvard Medical School, 243 Charles Street, Boston, MA 02155, USA.
Ophthalmol Clin North Am. 2003 Mar;16(1):127-35, viii. doi: 10.1016/s0896-1549(02)00063-9.
Laser subepithelial keratomileusis (LASEK) has become a viable alternative to photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK) in selected patients. LASEK may decrease the complications associated with PRK, including postoperative pain and slow visual rehabilitation. In this article, the authors present the visual outcomes and complication rates of LASEK based on the retrospective case review of 101 consecutive patients (163 eyes) treated with LASEK surgery over the past 6 years. Seventy-eight percent of these eyes showed complete epithelial healing by day 3, and there were no incidents of recurrent erosions. As with LASIK, the achieved correction for LASEK was greater than the treatment dose (requiring undercorrection nomogram adjustments). Mean logMAR UCVA was 0.03 (20/20) at 1 year. LASEK seems to be a safe and effective option for patients who request refractive surgery.
对于部分特定患者而言，准分子上皮下角膜磨镶术（LASEK）已成为准分子激光角膜切削术（PRK）和准分子原位角膜磨镶术（LASIK）之外的可行选择。LASEK可能会减少与PRK相关的并发症，包括术后疼痛和视力恢复缓慢。在本文中，作者基于对过去6年中连续接受LASEK手术的101例患者（163只眼）的回顾性病例分析，呈现了LASEK的视觉效果和并发症发生率。这些眼中有78%在第3天显示上皮完全愈合，且无复发性糜烂事件发生。与LASIK一样，LASEK所实现的矫正量大于治疗剂量（需要调整欠矫列线图）。术后1年平均LogMAR最佳矫正视力（UCVA）为0.03（20/20）。对于要求进行屈光手术的患者，LASEK似乎是一种安全有效的选择。
